1321 related articles for article (PubMed ID: 32997882)
1. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
4. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
5. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
6. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
[TBL] [Abstract][Full Text] [Related]
7. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
9. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.
Ortolan A; Lorenzin M; Tadiotto G; Russo FP; Oliviero F; Felicetti M; D'Incà R; Favero M; Piaserico S; Doria A; Ramonda R
Clin Rheumatol; 2019 Oct; 38(10):2843-2850. PubMed ID: 31254236
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
[TBL] [Abstract][Full Text] [Related]
12. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
14. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
Cheng YM; Wang CC; Kao JH
Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population.
Deng D; George J; Pasupathy D; Wah Cheung N
Diabetes Res Clin Pract; 2021 Apr; 174():108757. PubMed ID: 33744378
[TBL] [Abstract][Full Text] [Related]
16. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population.
Ciardullo S; Perseghin G
Liver Int; 2021 Jun; 41(6):1290-1293. PubMed ID: 33590934
[TBL] [Abstract][Full Text] [Related]
19. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
20. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
